Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: The LITE (Liposomal doxorubicin–Investigational chemotherapy–Tissue doppler imaging Evaluation) randomized pilot study
Authors:
- Marzia LotrionteMLMarzia Lotrionte
- Giovanni PalazzoniGPGiovanni Palazzoni
- Antonio AbbateAAAntonio Abbate
- Eugenia De MarcoEMEugenia De Marco
- Eleonora MezzaromaEMEleonora Mezzaroma
- Silvia Di PersioSPSilvia Di Persio
- Giacomo FratiGiacomo Frati
- Francesco LoperfidoFLFrancesco Loperfido
- Giuseppe Biondi-ZoccaiGiuseppe Biondi-Zoccai
- 1 August 2013
- journal article
- Published by Elsevier in International Journal of Cardiology
- Vol. 167 (3) , 1055-1057
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in ChildrenJournal of Clinical Oncology, 2012
- Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trialsBMC Cancer, 2010
- Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-pointsInternational Journal of Cardiology, 2009
- Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic reviewAnnals of Oncology, 2002
- Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic reviewAnnals of Oncology, 2002
- Anthracycline-Induced CardiotoxicityAnnals of Internal Medicine, 1996